SALTZ-IFL

Regimen

Experimental
IFL: irinotecan + bolus 5-FU/LV (Saltz schedule)
Control
Bolus 5-FU/LV alone; irinotecan alone as third arm

Population

Metastatic CRC, 1L, previously untreated; established irinotecan-containing chemotherapy as 1L standard.

Key finding

1L mCRC: IFL vs 5-FU/LV: mPFS 7.0 vs 4.3 mo (p=0.004); ORR 39% vs 21% (p<0.001); mOS 14.8 vs 12.6 mo (p=0.04); irinotecan alone showed no advantage over 5-FU/LV

Source: PMID 11006366

Timeline

    Guideline citations

    • NCCN Colon (p.2)
    • NCCN Rectal (p.2)